Rapport Therapeutics, Inc. (RAPP)
| Market Cap | 1.61B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -111.48M |
| Shares Out | 47.80M |
| EPS (ttm) | -2.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 189,415 |
| Open | 35.40 |
| Previous Close | 35.40 |
| Day's Range | 33.31 - 35.88 |
| 52-Week Range | 7.73 - 42.27 |
| Beta | n/a |
| Analysts | Strong Buy |
| Price Target | 48.50 (+43.75%) |
| Earnings Date | May 8, 2026 |
About RAPP
Rapport Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company that focuses on the discovery and development of transformational small molecule medicines for patients suffering from central nervous system (CNS) disorders. The company’s lead product candidate is receptor associated protein (RAP)-219, an investigational small molecule that is designed to inhibit TARPy8-containing AMPARs with picomolar affinity for the treatment of focal epilepsy and other CNS disorders, including peripheral neuropathic pain and bipolar disorde... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for RAPP stock is "Strong Buy." The 12-month stock price target is $48.5, which is an increase of 43.75% from the latest price.
News
Rapport Therapeutics Presents RAP-219 Focal Onset Seizure Phase 2a Follow-up Period Results Demonstrating Sustained Seizure Reduction at the 2026 American Academy of Neurology Annual Meeting
Clinically meaningful efficacy demonstrated in the 8-week follow-up period (weeks 9-16), with a 90% median reduction in clinical seizures over baseline in weeks 9-12 and a 59% median reduction in clin...
Communiqué de mise à disposition du rapport financier annuel 2025
A Paris, le 8 avril 2026 COMMUNIQUE INFORMATION REGLEMENTEE Communiqué précisant les modalités de mise à disposition du Rapport financier annuel 2025 de Crédit Mutuel Home Loan SFH Crédit Mutuel Home ...
Neuphonic and Rapport Bring Real-Time Digital Humans to Everyday Hardware
LONDON--(BUSINESS WIRE)--Neuphonic and Rapport (a division of Speech Graphics) today announced a partnership to deliver what they believe is among the first fully real-time, photorealistic digital hum...
Rapport Therapeutics to Present New Phase 2 Treatment Follow-Up Data for RAP-219 in Focal Onset Seizures at the 2026 American Academy of Neurology Annual Meeting
BOSTON and SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and d...
CRCAM Toulouse 31 - Rapport financier annuel 2025
Ci-joint le rapport financier annuel 2025 Attachment Rapport Financier CRCAM 2025
Mise à disposition des éléments préparatoires à l'AG du 27/03/2026 - Rapport Financier Annuel 2025
Mise à disposition des éléments préparatoires à l'AG du 27/03/2026 - Rapport Financier Annuel 2025 Vous trouverez en attaché les informations préparatoires aux Assemblées Générales Ordinaires et Ext...
Rapport Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The lead program demonstrated strong efficacy and tolerability in focal-onset seizures, with phase III global trials set to begin soon. Strategic partnerships, a robust pipeline, and a long-acting injectable formulation position the company for growth and extended IP protection.
Rapport Therapeutics Transcript: The Citizens Life Sciences Conference 2026
RAP-219, a selective TARP gamma-8 AMPA modulator, showed unprecedented efficacy and safety in Phase 2 epilepsy trials, with global Phase 3 studies underway and expansion into bipolar mania and tonic-clonic seizures. A long-acting injectable formulation and strong financial position further differentiate the program.
Rapport Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
RAP-219's lead program demonstrated robust and consistent activity in patients with focal onset seizures (FOS) in Phase 2a trial; initiation of Phase 3 program expected in the second quarter of 2026 R...
Rapport Therapeutics and Tenacia Biotechnology Announce Strategic Collaboration for the Development and Commercialization of RAP-219 in Greater China
Partnership leverages Tenacia's expertise in central nervous system (CNS) drug development and commercialization to accelerate U.S. and global development of RAP-219 Tenacia obtains exclusive rights t...
Rapport Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
RAP-219 demonstrated strong efficacy and safety in refractory focal-onset seizures, enabling accelerated phase III trials in 2026. Market research supports best-in-class potential, with a multi-billion dollar opportunity and expansion into bipolar mania and pain. Funding extends into 2029, supporting multiple clinical milestones.
Rapport Therapeutics to Participate in Upcoming Investor Conferences
BOSTON and SAN DIEGO, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and de...
Fantôme Rapport Launches in English — A Romance, Horror, and Mystery Adventure Aboard a Ghostly Luxury Liner
OSAKA, Japan--(BUSINESS WIRE)-- #anime--The English Ver of Fantôme Rapport launches Jan 16, 2026 (JST). A romantic horror mystery aboard a ghostly luxury liner, where bonds shape your fate.
Rapport Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference
Rapport Therapeutics presented strong phase 2 results for RAP-219 in focal onset seizures, with plans to start pivotal trials and expand into additional indications, including a first-in-class long-acting injectable. The company highlighted significant market opportunities and a robust pipeline, with key data readouts expected through 2027.
Rapport Therapeutics Announces Accelerated Initiation of RAP-219 Phase 3 Program, Expansion of Epilepsy Portfolio, and Continued Progress Across the Pipeline
U.S. Food and Drug Administration (FDA) allows advancement of RAP-219 into registrational trials for focal onset seizures (FOS); accelerated initiation of Phase 3 program expected in the second quarte...
Rapport Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference
BOSTON and SAN DIEGO, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and de...
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219's Clinical Response in Patients with Focal Onset Seizures
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients'...
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting
BOSTON and SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and de...
Rapport Therapeutics Transcript: Jefferies London Healthcare Conference 2025
RAP-219, a precision neuroscience candidate, showed over 70% seizure reduction and strong tolerability in phase II, with pivotal studies planned for 2026 and a long-acting injectable in development. The program targets a large, treatment-resistant epilepsy market and is expanding into bipolar mania.
Rapport Therapeutics Transcript: Stifel 2025 Healthcare Conference
RAP-219, a precision AMPA modulator, showed robust efficacy and tolerability in epilepsy, with phase three trials set to begin by Q3 2026. Expansion into bipolar mania and other indications is underway, supported by strong financials and a multi-billion dollar market outlook.
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update
Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with toplin...
Rapport Acquires Aquifer Motion, Becoming the First Company to Offer Real-Time, AI-Powered Avatars with Full-Body Animation
SAN FRANCISCO & AUSTIN, Texas & EDINBURGH, Scotland--(BUSINESS WIRE)-- #AI--Rapport Acquires Aquifer Motion, Becoming the First Company to Offer Real-Time, AI-Powered Avatars with Full-Body Animation.
Rapport Therapeutics Transcript: TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit
Phase 2 data for RAP-219 in drug-resistant focal epilepsy showed robust efficacy and a favorable safety profile, supporting broad clinical adoption and a significant market opportunity. Two Phase 3 trials are planned for 2026, with strong financial backing and expanded development into bipolar mania and pain.
Crédit Agricole Normandie Seine : Rapport financier semestriel 06 2025
Crédit Agricole Normandie Seine : Rapport financier semestriel 2025 Le rapport financier semestriel au 30/06/2025 de la Caisse régionale de Crédit Agricole Mutuel Normandie Seine a été déposé auprès d...